;PMID: 12604681
;source_file_817.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..152] = [t:52..152]
;2)section:[e:156..193] = [t:156..193]
;3)section:[e:197..297] = [t:197..297]
;4)sentence:[e:301..596] = [t:301..596]
;5)sentence:[e:597..808] = [t:597..808]
;6)sentence:[e:809..919] = [t:809..919]
;7)sentence:[e:920..1000] = [t:920..1000]
;8)sentence:[e:1001..1221] = [t:1001..1221]
;9)sentence:[e:1222..1391] = [t:1222..1391]
;10)sentence:[e:1392..1527] = [t:1392..1527]
;11)sentence:[e:1528..1619] = [t:1528..1619]
;12)sentence:[e:1620..1706] = [t:1620..1706]
;13)sentence:[e:1707..1962] = [t:1707..1962]
;14)sentence:[e:1963..2059] = [t:1963..2059]
;15)section:[e:2063..2108] = [t:2063..2108]

;section 0 Span:0..46
;J Pharmacol Exp Ther. 2003 Mar;304(3):1048-54.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..11] Pharmacol) (NNP:[12..15] Exp)
        (NNP:[16..20] Ther) (.:[20..21] .) ('':[22..26] 2003)
        (CC:[27..35] Mar;304-LRB-) (CD:[35..36] 3) (-RRB-:[36..37] -RRB-)
        (CD:[37..42] :1048) (IN:[42..43] -) (CD:[43..45] 54) (.:[45..46] .)))

;sentence 1 Span:52..152
;Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines
;in  rat hepatoma cells.
;[85..91]:cyp450:"CYP2E1"
;[119..128]:substance:"cytokines"
(SENT
  (NP-HLN
    (NP (NNS:[52..62] Mechanisms))
    (PP (IN:[63..65] of)
      (NP
        (NP (RB:[66..70] down) (HYPH:[70..71] -) (NN:[71..81] regulation))
        (PP (IN:[82..84] of)
          (NP (NN:[85..91] CYP2E1) (NN:[92..102] expression)))
        (PP (IN:[103..105] by)
          (NP (JJ:[106..118] inflammatory) (NNS:[119..128] cytokines)))))
    (PP-LOC (IN:[129..131] in)
      (NP (NN:[133..136] rat) (NN:[137..145] hepatoma) (NNS:[146..151] cells)))
    (.:[151..152] .)))

;section 2 Span:156..193
;Hakkola J, Hu Y, Ingelman-Sundberg M.
(SEC
  (FRAG (NNP:[156..163] Hakkola) (NNP:[164..166] J,) (NNP:[167..169] Hu)
        (NNP:[170..171] Y) (,:[171..172] ,) (NNP:[173..181] Ingelman)
        (HYPH:[181..182] -) (NNP:[182..190] Sundberg) (NNP:[191..193] M.)))

;section 3 Span:197..297
;Department of Pharmacology and Toxicology, University of Oulu, Oulu, Finland.
; jukka.hakkola@oulu.fi
(SEC
  (FRAG (NNP:[197..207] Department) (IN:[208..210] of)
        (NNP:[211..223] Pharmacology) (CC:[224..227] and)
        (NNP:[228..238] Toxicology) (,:[238..239] ,) (NNP:[240..250] University)
        (IN:[251..253] of) (NNP:[254..258] Oulu) (,:[258..259] ,)
        (NNP:[260..264] Oulu) (,:[264..265] ,) (NNP:[266..273] Finland)
        (MD:[273..274] .) (VB:[276..281] jukka) (.:[281..297] .hakkola@oulu.fi)))

;sentence 4 Span:301..596
;CYP2E1 is one of the major cytochrome P450 forms whose expression is strongly
; inhibited by inflammatory cytokines in humans and rodents. In the present
;study,  we have used the Fao rat hepatoma cell line that constitutively
;expresses CYP2E1  enzyme to investigate mechanisms of cytokine action.
;[301..307]:cyp450:"CYP2E1"
;[328..343]:cyp450:"cytochrome P450"
;[406..415]:substance:"cytokines"
;[536..550]:cyp450:"CYP2E1  enzyme"
;[580..588]:substance:"cytokine"
(SENT
  (S
    (NP-SBJ (NN:[301..307] CYP2E1))
    (VP (VBZ:[308..310] is)
      (NP-PRD
        (NP (CD:[311..314] one))
        (PP (IN:[315..317] of)
          (NP
            (NP (DT:[318..321] the) (JJ:[322..327] major)
              (NML (NN:[328..338] cytochrome) (NN:[339..343] P450))
              (NNS:[344..349] forms))
            (SBAR
              (WHNP-1 (WP$:[350..355] whose) (NN:[356..366] expression))
              (S
                (NP-SBJ-1 (-NONE-:[366..366] *T*))
                (VP (VBZ:[367..369] is)
                  (ADVP (RB:[370..378] strongly))
                  (VP (VBN:[380..389] inhibited)
                    (NP-1 (-NONE-:[389..389] *))
                    (PP (IN:[390..392] by)
                      (NP-LGS (JJ:[393..405] inflammatory)
                              (NNS:[406..415] cytokines)))
                    (PP-LOC (IN:[416..418] in)
                      (NP (NNS:[419..425] humans) (CC:[426..429] and)
                          (NNS:[430..437] rodents)))))))))))
    (.:[437..438] .))
  (S
    (PP (IN:[439..441] In)
      (NP (DT:[442..445] the) (JJ:[446..453] present) (NN:[454..459] study)))
    (,:[459..460] ,)
    (NP-SBJ (PRP:[462..464] we))
    (VP (VBP:[465..469] have)
      (VP (VBN:[470..474] used)
        (NP
          (NP (DT:[475..478] the)
            (NML (NN:[479..482] Fao) (NN:[483..486] rat))
            (NN:[487..495] hepatoma) (NN:[496..500] cell) (NN:[501..505] line))
          (SBAR
            (WHNP-2 (WDT:[506..510] that))
            (S
              (NP-SBJ-2 (-NONE-:[510..510] *T*))
              (ADVP (RB:[511..525] constitutively))
              (VP (VBZ:[526..535] expresses)
                (NP (NN:[536..542] CYP2E1) (NN:[544..550] enzyme))))))
        (S-PRP
          (NP-SBJ (-NONE-:[550..550] *))
          (VP (TO:[551..553] to)
            (VP (VB:[554..565] investigate)
              (NP
                (NP (NNS:[566..576] mechanisms))
                (PP (IN:[577..579] of)
                  (NP (NN:[580..588] cytokine) (NN:[589..595] action)))))))))
    (.:[595..596] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[301..596]::S:S:

;sentence 5 Span:597..808
;The cells were treated with  interleukin (IL)-1beta, tumor necrosis
;factor-alpha (TNFalpha), or IL-6 for 24  or 72 h, and the expression of
;CYP2E1 was monitored at the transcriptional,  mRNA, and protein levels.
;[626..648]:substance:"interleukin (IL)-1beta"
;[650..677]:substance:"tumor necrosis factor-alpha"
;[679..687]:substance:"TNFalpha"
;[693..697]:substance:"IL-6"
;[702..704]:quantitative-value:"24"
;[709..711]:quantitative-value:"72"
;[712..713]:quantitative-units:"h"
;[737..743]:cyp450:"CYP2E1"
;[783..787]:substance:"mRNA"
;[793..800]:substance:"protein"
(SENT
  (S
    (S
      (NP-SBJ-4 (DT:[597..600] The) (NNS:[601..606] cells))
      (VP (VBD:[607..611] were)
        (VP (VBN:[612..619] treated)
          (NP-4 (-NONE-:[619..619] *))
          (PP-MNR (IN:[620..624] with)
            (NP
              (NP
                (NML
                  (NML (NN:[626..637] interleukin))
                  (NML (-LRB-:[638..639] -LRB-) (NN:[639..641] IL)
                       (-RRB-:[641..642] -RRB-)))
                (HYPH:[642..643] -) (NN:[643..648] 1beta))
              (,:[648..649] ,)
              (NP
                (NP
                  (NML (NN:[650..655] tumor) (NN:[656..664] necrosis)
                       (NN:[665..671] factor))
                  (HYPH:[671..672] -) (SYM:[672..677] alpha))
                (NP (-LRB-:[678..679] -LRB-) (NN:[679..687] TNFalpha)
                    (-RRB-:[687..688] -RRB-)))
              (,:[688..689] ,) (CC:[690..692] or)
              (NP (NN:[693..697] IL-6))))
          (PP-TMP (IN:[698..701] for)
            (NP
              (NP (CD:[702..704] 24)
                (NML-3 (-NONE-:[704..704] *P*)))
              (CC:[706..708] or)
              (NP (CD:[709..711] 72)
                (NML-3 (NN:[712..713] h))))))))
    (,:[713..714] ,) (CC:[715..718] and)
    (S
      (NP-SBJ-2
        (NP (DT:[719..722] the) (NN:[723..733] expression))
        (PP (IN:[734..736] of)
          (NP (NN:[737..743] CYP2E1))))
      (VP (VBD:[744..747] was)
        (VP (VBN:[748..757] monitored)
          (NP-2 (-NONE-:[757..757] *))
          (PP (IN:[758..760] at)
            (NP (DT:[761..764] the)
              (NML
                (NML (JJ:[765..780] transcriptional)
                  (NML-1 (-NONE-:[780..780] *P*)))
                (,:[780..781] ,)
                (NML (NN:[783..787] mRNA)
                  (NML-1 (-NONE-:[787..787] *P*)))
                (,:[787..788] ,) (CC:[789..792] and)
                (NML (NN:[793..800] protein)
                  (NML-1 (NNS:[801..807] levels)))))))))
    (.:[807..808] .)))

;sentence 6 Span:809..919
;All three cytokines decreased the CYP2E1 mRNA levels  after 24 h, and the
;effect was even stronger after 72 h.
;[819..828]:substance:"cytokines"
;[843..854]:substance:"CYP2E1 mRNA"
;[869..871]:quantitative-value:"24"
;[872..873]:quantitative-units:"h"
;[914..916]:quantitative-value:"72"
;[917..918]:quantitative-units:"h"
(SENT
  (S
    (S
      (NP-SBJ (DT:[809..812] All) (CD:[813..818] three)
              (NNS:[819..828] cytokines))
      (VP (VBD:[829..838] decreased)
        (NP (DT:[839..842] the)
           (NN:[843..849] CYP2E1) (NN:[850..854] mRNA)
          (NNS:[855..861] levels))
        (PP-TMP (IN:[863..868] after)
          (NP (CD:[869..871] 24) (NN:[872..873] h)))))
    (,:[873..874] ,) (CC:[875..878] and)
    (S
      (NP-SBJ (DT:[879..882] the) (NN:[883..889] effect))
      (VP (VBD:[890..893] was)
        (ADJP-PRD (RB:[894..898] even) (JJR:[899..907] stronger))
        (PP-TMP (IN:[908..913] after)
          (NP (CD:[914..916] 72) (NN:[917..918] h)))))
    (.:[918..919] .)))

;sentence 7 Span:920..1000
;In contrast,  significant inhibition of CYP2E1 protein was seen only after 72
;h.
;[960..974]:cyp450:"CYP2E1 protein"
;[995..997]:quantitative-value:"72"
;[998..999]:quantitative-units:"h"
(SENT
  (S
    (PP (IN:[920..922] In)
      (NP (NN:[923..931] contrast)))
    (,:[931..932] ,)
    (NP-SBJ-1
      (NP (JJ:[934..945] significant) (NN:[946..956] inhibition))
      (PP (IN:[957..959] of)
        (NP (NN:[960..966] CYP2E1) (NN:[967..974] protein))))
    (VP (VBD:[975..978] was)
      (VP (VBN:[979..983] seen)
        (NP-1 (-NONE-:[983..983] *))
        (ADVP (RB:[984..988] only))
        (PP-TMP (IN:[989..994] after)
          (NP (CD:[995..997] 72) (NN:[998..999] h)))))
    (.:[999..1000] .)))

;sentence 8 Span:1001..1221
;In  transfection assays using a CYP2E1 5' -3685 to +29-luciferase construct,
;it was  found that IL-6 inhibited gene transcription after 24 h, but a
;similar effect by  IL-1beta and TNFalpha was registered only after 72 h.
;[1033..1039]:cyp450:"CYP2E1"
;[1056..1066]:substance:"luciferase"
;[1097..1101]:substance:"IL-6"
;[1137..1139]:quantitative-value:"24"
;[1140..1141]:quantitative-units:"h"
;[1168..1176]:substance:"IL-1beta"
;[1181..1189]:substance:"TNFalpha"
;[1216..1218]:quantitative-value:"72"
;[1219..1220]:quantitative-units:"h"
(SENT
  (S
    (PP-LOC (IN:[1001..1003] In)
      (NP
        (NP (NN:[1005..1017] transfection) (NNS:[1018..1024] assays))
        (VP (VBG:[1025..1030] using)
          (NP (DT:[1031..1032] a)
            (NML
              (NML (NN:[1033..1039] CYP2E1)
                (NML (CD:[1040..1041] 5) (SYM:[1041..1042] '))
                (NML
                  (NML (SYM:[1043..1044] -) (CD:[1044..1048] 3685))
                  (PP (TO:[1049..1051] to)
                    (NP (SYM:[1052..1053] +) (CD:[1053..1055] 29)))))
              (HYPH:[1055..1056] -) (NN:[1056..1066] luciferase))
            (NN:[1067..1076] construct)))))
    (,:[1076..1077] ,)
    (NP-SBJ-3
      (NP (PRP:[1078..1080] it))
      (SBAR-2 (-NONE-:[1080..1080] *EXP*)))
    (VP (VBD:[1081..1084] was)
      (VP (VBN:[1086..1091] found)
        (NP-3 (-NONE-:[1091..1091] *))
        (SBAR-2 (IN:[1092..1096] that)
          (S
            (S
              (NP-SBJ (NN:[1097..1101] IL-6))
              (VP (VBD:[1102..1111] inhibited)
                (NP (NN:[1112..1116] gene) (NN:[1117..1130] transcription))
                (PP-TMP (IN:[1131..1136] after)
                  (NP (CD:[1137..1139] 24) (NN:[1140..1141] h)))))
            (,:[1141..1142] ,) (CC:[1143..1146] but)
            (S
              (NP-SBJ-1
                (NP (DT:[1147..1148] a) (JJ:[1149..1156] similar)
                    (NN:[1157..1163] effect))
                (PP (IN:[1164..1166] by)
                  (NP (NN:[1168..1176] IL-1beta) (CC:[1177..1180] and)
                      (NN:[1181..1189] TNFalpha))))
              (VP (VBD:[1190..1193] was)
                (VP (VBN:[1194..1204] registered)
                  (NP-1 (-NONE-:[1204..1204] *))
                  (ADVP (RB:[1205..1209] only))
                  (PP-TMP (IN:[1210..1215] after)
                    (NP (CD:[1216..1218] 72) (NN:[1219..1220] h))))))))))
    (.:[1220..1221] .)))

;sentence 9 Span:1222..1391
;Using 5' deletions of the  CYP2E1 5'-reporter construct a responsive region
;for the IL-6 effect was located  to -669 to -507 base pairs in the CYP2E1
;5'-flanking region.
;[1249..1255]:cyp450:"CYP2E1"
;[1306..1310]:substance:"IL-6"
;[1365..1371]:cyp450:"CYP2E1"
(SENT
  (S
    (S-MNR
      (NP-SBJ (-NONE-:[1222..1222] *))
      (VP (VBG:[1222..1227] Using)
        (NP
          (NML (CD:[1228..1229] 5) (SYM:[1229..1230] '))
          (NNS:[1231..1240] deletions))
        (PP (IN:[1241..1243] of)
          (NP (DT:[1244..1247] the)
            (NML
              (NML (NN:[1249..1255] CYP2E1) (CD:[1256..1257] 5)
                   (SYM:[1257..1258] '))
              (HYPH:[1258..1259] -) (NN:[1259..1267] reporter))
            (NN:[1268..1277] construct)))))
    (NP-SBJ-1
      (NP (DT:[1278..1279] a) (JJ:[1280..1290] responsive)
          (NN:[1291..1297] region))
      (PP (IN:[1298..1301] for)
        (NP (DT:[1302..1305] the) (NN:[1306..1310] IL-6)
            (NN:[1311..1317] effect))))
    (VP (VBD:[1318..1321] was)
      (VP (VBN:[1322..1329] located)
        (NP-1 (-NONE-:[1329..1329] *))
        (PP (TO:[1331..1333] to)
          (NP
            (NP (SYM:[1334..1335] -) (CD:[1335..1338] 669))
            (PP (TO:[1339..1341] to)
              (NP
                (NML (SYM:[1342..1343] -) (CD:[1343..1346] 507))
                (NN:[1347..1351] base) (NNS:[1352..1357] pairs)))
            (PP-LOC (IN:[1358..1360] in)
              (NP (DT:[1361..1364] the)
                (ADJP
                  (NML (NN:[1365..1371] CYP2E1) (CD:[1372..1373] 5)
                       (SYM:[1373..1374] '))
                  (HYPH:[1374..1375] -) (VBG:[1375..1383] flanking))
                (NN:[1384..1390] region)))))))
    (.:[1390..1391] .)))

;sentence 10 Span:1392..1527
;Interestingly,  IL-1beta, but not TNFalpha, was found to reduce hepatocyte
;nuclear factor  (HNF)-1alpha binding to the CYP2E1 promotor.
;[1408..1416]:substance:"IL-1beta"
;[1426..1434]:substance:"TNFalpha"
;[1456..1495]:substance:"hepatocyte nuclear factor  (HNF)-1alpha"
;[1511..1517]:cyp450:"CYP2E1"
;[1518..1526]:substance:"promotor"
(SENT
  (S
    (ADVP (RB:[1392..1405] Interestingly))
    (,:[1405..1406] ,)
    (NP-SBJ-1
      (NP (NN:[1408..1416] IL-1beta))
      (,:[1416..1417] ,)
      (CONJP (CC:[1418..1421] but) (RB:[1422..1425] not))
      (NP (NN:[1426..1434] TNFalpha)))
    (,:[1434..1435] ,)
    (VP (VBD:[1436..1439] was)
      (VP (VBN:[1440..1445] found)
        (S
          (NP-SBJ-1 (-NONE-:[1445..1445] *))
          (VP (TO:[1446..1448] to)
            (VP (VB:[1449..1455] reduce)
              (NP
                (NP
                  (NML
                    (NML
                      (NML (NN:[1456..1466] hepatocyte)
                           (JJ:[1467..1474] nuclear) (NN:[1475..1481] factor))
                      (NML (-LRB-:[1483..1484] -LRB-) (NN:[1484..1487] HNF)
                           (-RRB-:[1487..1488] -RRB-)))
                    (HYPH:[1488..1489] -) (NN:[1489..1495] 1alpha))
                  (VBG:[1496..1503] binding))
                (PP (TO:[1504..1506] to)
                  (NP (DT:[1507..1510] the) (NN:[1511..1517] CYP2E1)
                      (NN:[1518..1526] promotor)))))))))
    (.:[1526..1527] .)))

;sentence 11 Span:1528..1619
;However, the transactivation  function of HNF-1alpha was found to be impaired
;in Fao cells.
;[1570..1580]:substance:"HNF-1alpha"
(SENT
  (S
    (ADVP (RB:[1528..1535] However))
    (,:[1535..1536] ,)
    (NP-SBJ-1
      (NP (DT:[1537..1540] the) (NN:[1541..1556] transactivation)
          (NN:[1558..1566] function))
      (PP (IN:[1567..1569] of)
        (NP (NN:[1570..1580] HNF-1alpha))))
    (VP (VBD:[1581..1584] was)
      (VP (VBN:[1585..1590] found)
        (S
          (NP-SBJ-1 (-NONE-:[1590..1590] *))
          (VP (TO:[1591..1593] to)
            (VP (VB:[1594..1596] be)
              (VP (VBN:[1597..1605] impaired)
                (NP-1 (-NONE-:[1605..1605] *))
                (PP-LOC (IN:[1606..1608] in)
                  (NP (NN:[1609..1612] Fao) (NNS:[1613..1618] cells)))))))))
    (.:[1618..1619] .)))

;sentence 12 Span:1620..1706
;In mouse primary  hepatocytes, IL-1beta decreased HNF-1alpha-mediated
;transactivation.
;[1651..1659]:substance:"IL-1beta"
;[1670..1680]:substance:"HNF-1alpha"
(SENT
  (S
    (PP-LOC (IN:[1620..1622] In)
      (NP (NN:[1623..1628] mouse) (JJ:[1629..1636] primary)
          (NNS:[1638..1649] hepatocytes)))
    (,:[1649..1650] ,)
    (NP-SBJ (NN:[1651..1659] IL-1beta))
    (VP (VBD:[1660..1669] decreased)
      (NP
        (ADJP (NN:[1670..1680] HNF-1alpha) (HYPH:[1680..1681] -)
              (VBN:[1681..1689] mediated))
        (NN:[1690..1705] transactivation)))
    (.:[1705..1706] .)))

;sentence 13 Span:1707..1962
;In  conclusion, our data indicate that inflammatory cytokines inhibit CYP2E1 
;expression by multiple mechanisms, including control of HNF-1alpha function
;and  regulation of other transcriptional factors acting on the CYP2E1
;5'-upstream  regulatory region.
;[1759..1768]:substance:"cytokines"
;[1777..1783]:cyp450:"CYP2E1"
;[1841..1851]:substance:"HNF-1alpha"
;[1886..1909]:substance:"transcriptional factors"
;[1924..1930]:cyp450:"CYP2E1"
(SENT
  (S
    (PP (IN:[1707..1709] In)
      (NP (NN:[1711..1721] conclusion)))
    (,:[1721..1722] ,)
    (NP-SBJ (PRP$:[1723..1726] our) (NNS:[1727..1731] data))
    (VP (VBP:[1732..1740] indicate)
      (SBAR (IN:[1741..1745] that)
        (S
          (NP-SBJ (JJ:[1746..1758] inflammatory) (NNS:[1759..1768] cytokines))
          (VP (VBP:[1769..1776] inhibit)
            (NP (NN:[1777..1783] CYP2E1) (NN:[1785..1795] expression))
            (PP-MNR (IN:[1796..1798] by)
              (NP
                (NP (JJ:[1799..1807] multiple) (NNS:[1808..1818] mechanisms))
                (,:[1818..1819] ,)
                (PP (VBG:[1820..1829] including)
                  (NP
                    (NP
                      (NP (NN:[1830..1837] control))
                      (PP (IN:[1838..1840] of)
                        (NP (NN:[1841..1851] HNF-1alpha)
                            (NN:[1852..1860] function))))
                    (CC:[1861..1864] and)
                    (NP
                      (NP (NN:[1866..1876] regulation))
                      (PP (IN:[1877..1879] of)
                        (NP
                          (NP (JJ:[1880..1885] other)
                             (JJ:[1886..1901] transcriptional)
                             (NNS:[1902..1909] factors))
                          (VP (VBG:[1910..1916] acting)
                            (PP-CLR (IN:[1917..1919] on)
                              (NP (DT:[1920..1923] the)
                                (NML (NN:[1924..1930] CYP2E1)
                                     (CD:[1931..1932] 5) (SYM:[1932..1933] '))
                                (HYPH:[1933..1934] -) (JJ:[1934..1942] upstream)
                                 (JJ:[1944..1954] regulatory)
                                 (NN:[1955..1961] region)))))))))))))))
    (.:[1961..1962] .)))

;sentence 14 Span:1963..2059
;In addition, regulation of factors of importance for the  CYP2E1 mRNA
;stability may be involved.
;[2021..2032]:substance:"CYP2E1 mRNA"
(SENT
  (S
    (PP (IN:[1963..1965] In)
      (NP (NN:[1966..1974] addition)))
    (,:[1974..1975] ,)
    (NP-SBJ-1
      (NP (NN:[1976..1986] regulation))
      (PP (IN:[1987..1989] of)
        (NP
          (NP (NNS:[1990..1997] factors))
          (PP (IN:[1998..2000] of)
            (NP
              (NP (NN:[2001..2011] importance))
              (PP (IN:[2012..2015] for)
                (NP (DT:[2016..2019] the)
                   (NN:[2021..2027] CYP2E1) (NN:[2028..2032] mRNA)
                  (NN:[2033..2042] stability))))))))
    (VP (MD:[2043..2046] may)
      (VP (VB:[2047..2049] be)
        (VP (VBN:[2050..2058] involved)
          (NP-1 (-NONE-:[2058..2058] *)))))
    (.:[2058..2059] .)))

;section 15 Span:2063..2108
;PMID: 12604681 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2063..2067] PMID) (::[2067..2068] :) (CD:[2069..2077] 12604681)
        (IN:[2078..2079] -LSB-) (NNP:[2079..2085] PubMed) (HYPH:[2086..2087] -)
        (JJ:[2088..2095] indexed) (IN:[2096..2099] for)
        (NNP:[2100..2108] MEDLINE-RSB-)))
